Details for New Drug Application (NDA): 207367
✉ Email this page to a colleague
NDA 207367 describes BUDESONIDE, which is a drug marketed by Padagis Israel, Amneal Pharms, Aurobindo Pharma Usa, Barr Labs Div Teva, Dr Reddys Labs Sa, Natco, Rising, Sciecure Pharma Inc, Zydus Pharms, Apotex Inc, Cipla, Eugia Pharma, Impax Labs Inc, Lupin, Nephron, Sandoz, Sun Pharm, Teva Pharms, Teva Pharms Usa, Actavis Labs Fl Inc, and Mylan, and is included in twenty-one NDAs. It is available from thirty-five suppliers. Additional details are available on the BUDESONIDE profile page.
The generic ingredient in BUDESONIDE is budesonide. There are twenty-two drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the budesonide profile page.
The generic ingredient in BUDESONIDE is budesonide. There are twenty-two drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the budesonide profile page.
Summary for 207367
| Tradename: | BUDESONIDE |
| Applicant: | Rising |
| Ingredient: | budesonide |
| Patents: | 0 |
Pharmacology for NDA: 207367
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 207367
Suppliers and Packaging for NDA: 207367
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BUDESONIDE | budesonide | CAPSULE, DELAYED RELEASE;ORAL | 207367 | ANDA | Rising Pharmaceuticals, Inc. | 64980-255 | 64980-255-01 | 100 CAPSULE in 1 BOTTLE (64980-255-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, DELAYED RELEASE;ORAL | Strength | 3MG | ||||
| Approval Date: | Apr 7, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
